Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

Preliminary data from an ongoing Phase 2 trial evaluating satraplatin plus Taxol(R) (paclitaxel) in the first-line treatment of patients with advanced non-small cell lung cancer were also published in the ASCO educational book (Shipley, D. et al. Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer). Data from 24 patients were available for analysis; a total of approximately 40 patients are expected to be enrolled in the study. This preliminary analysis showed that satraplatin plus Taxol appears to have activity in this treatment setting. In an effort to reduce myelosuppression in the study, the satraplatin dose has been lowered to 70 mg/m2 from 80 mg/m2. The study continues to enroll and follow patients.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is not currently approved by the FDA in the United States, by the EMEA in the European Union or any other regulatory authority and no conclusions can or should be drawn regarding its safety and efficacy.

A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone- refractory prostate cancer whose prior chemotherapy has failed. Data from the trial on progression-free survival and on safety have been presented at recent medical conferences.

GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories.
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Tool Detects Risk for Undiagnosed Diabetes, Plus: ... ALEXANDRIA, Va., April 28 A highly detailed,mathematical ... whether they likely have the disease and can ... associated with this now,epidemic illness, according to studies ...
... Fighting Blindness ... OWINGS MILLS, Md., April 27 Scientists employing a ... blind from,a condition known as Leber congenital amaurosis (LCA) -- ... trial, which was,funded in part by the Foundation Fighting Blindness, ...
Cached Medicine Technology:Drug Combo Could Lower Diabetes Complications and Costs 2Drug Combo Could Lower Diabetes Complications and Costs 3Drug Combo Could Lower Diabetes Complications and Costs 4Drug Combo Could Lower Diabetes Complications and Costs 5Gene Therapy Provides Vision to People who Were Nearly Blind 2
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... , , WASHINGTON , ... Center hosts a symposium exploring the future of cancer research on ... (GUMC).  Sponsored by the Ruesch Center for the Cure of Gastrointestinal ... Personalized Medicine & the Cure for Cancer, " will offer a ...
... Mo. , Feb. 12 The Reliv Kalogris ... $450,000 worth of children,s nutritional supplements to Haitian ... 3,000 cases of Reliv Now for Kids, a supplement containing ... to strengthen children,s health. Reliv produces nutritional supplements that are ...
... February 12, 2010 Giving chocolates to your Valentine on ... on a preliminary study from researchers at St. Michael,s Hospital. ... of Neurology in April, also found that eating chocolate may ... "Though more research is needed to determine whether chocolate is ...
... , Medication Delivered Under the Tongue May Be Alternative ... An oral allergy treatment administered in drops under the tongue ... are allergic to ragweed pollen, according to a study published today ... specialist at Allegheny General Hospital.   , Widely used in ...
... , 75% Say the U.S. ... Feb. 12 More than half (57%) of registered American voters ... Afghanistan , and half (52%) also approve of the way ... of the way the president is dealing with the country,s economic ...
... , THE WOODLANDS, Texas , Feb. 12 ... staff interested in learning the most important aspects to be aware ... for your particular practice are invited to attend a free webinar ... on Thursday, Feb. 18, 2010 . To register, ...
Cached Medicine News:Health News:GUMC's Lombardi Hosts Symposium Exploring Future of Cancer Research and Personalized Medicine 2Health News:GUMC's Lombardi Hosts Symposium Exploring Future of Cancer Research and Personalized Medicine 3Health News:Reliv Foundation Donates $450,000 In Nutritional Supplements to Haitian Relief Efforts 2Health News:Reliv Foundation Donates $450,000 In Nutritional Supplements to Haitian Relief Efforts 3Health News:Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment 2Health News:Majority of Americans Approve of President Obama's Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television 2Health News:Majority of Americans Approve of President Obama's Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television 3Health News:Majority of Americans Approve of President Obama's Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television 4Health News:What to Look for When Selecting an Electronic Health Record for Your Community Oncology Practice - Free Educational Webinar 2Health News:What to Look for When Selecting an Electronic Health Record for Your Community Oncology Practice - Free Educational Webinar 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: